Multiple myeloma

Clinical Medicine

Volumn 1, Issue 5, 2001, Pages 365-370

  Samson, Diana ^a   Singer, Charles ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISOLONE;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0034764342     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.1-5-365     Document Type: Review

References (28)

1. Herrinton LJ, Weiss NS, Olshan AF. Epidemiology of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds). Myeloma, biology and management. Oxford: Oxford University Press, 1998:150-86.
2. Van Riet I, Vanderkerken K, de Greef C, Van Camp B. Homing behaviour of the malignant cell clone in multiple myeloma. Review. Med Oncol 1998;15:154-64.
3. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Review. Br J Haematol 1998;103:902-10.
4. Nishida K, Tamura A, Nakazawa N, Ueda Y, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukaemia as detected by in situ hybridization. Blood 1997;90:526-34.
5. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical disorders. Genes Chromosomes Cancer 1997;18:84-93.
6. Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 1997;99:245-56.
7. UK Myeloma Forum. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2001 (in press).
8. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Review. Hematol Oncol Clin North Am 1997;11:71-87.
9. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
10. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and serum beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
11. Tricot G, Barlogie B, Jagannath S, Bracy D, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
12. Iggo N. Management of renal complications. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds). Myeloma, biology and management. Oxford: Oxford University Press, 1998:381-401.
13. Alexanian R, Haut A, Khan AU, Lane M, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-5.
14. Belch A, Shelley W, Bergsagel D, Wilson K, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988;57:94-9.
15. Salmon SE, Haut A, Bonnet JD, Amare M, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1983;1:453-61.
16. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992;339:200-5.
17. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
18. Samson D, Gaminara E, Newland A, Van de Pette J, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;ii:882-5.
19. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93.
20. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, et al. Long-term pamidroriate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
21. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party for Leukaemia in Adults. Br J Haematol 1998;100:317-25.
22. The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020-34.
23. Attal M, Harrousseau JL, Stoppa AM, Sotto JJ, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy for multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996;335:91-7.
24. Lenhoff S, Hjorth M, Holmberg E, Turesson I, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
25. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogcneic bone marrow transplantation. Blood 1997;90:4206-11.
26. Gahrton G, Svensson H, Cavo M, Apperly J, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-16.
27. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
28. Singhal S, Mehta J, Desikan R, Ayers D, et al. Antitumor activity of thalidomide in refractory myeloma. N Engl J Med 1999;341:1565-71.